2026-10-14T06:18:25Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34040787 2026-10-01T07:20:53Z category_37339 category_37348 category_37360 category_37366 portal_1012 item_type_6 month_year_10_2026

Supplementary Data1 from Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD Sarah B. Goldberg (15313365) Myung-Ju Ahn (15038427) Christina Baik (25154205) Javier De Castro Carpeño (25154208) Byoung Chul Cho (15032496) Adrianus Johannes de Langen (25154211) Mary J. Fidler (25154214) Jonathan W. Goldman (15033807) Bjørn Henning Grønberg (25154217) Hiroaki Akamatsu (15045695) Sang-We Kim (15046599) Yu Jung Kim (15034788) Xiuning Le (15037607) Kristen A. Marrone (16041842) Zofia Piotrowska (15313338) Jonathan W. Riess (14960592) Yoshimasa Shiraishi (15050538) Paula G. Fraenkel (22288096) Brayan Merchan Ruiz (25154220) Paul E. Smith (24685065) Kwan Ho Tang (15054848) Helena A. Yu (15055777) Cancer Cancer Biology Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Drug Targets Protein kinase & phosphatase drug targets Lung Cancer Oncogenes & Tumor Suppressors Oncogenes Small Molecule Agents Kinase inhibitors Supplementary Methods Supplementary Table S1. Representativeness of study participants. Supplementary Table S2. Summary of treatment-emergent adverse events. Supplementary Table S3. Patient demographics and baseline characteristics by EGFR C797S clonality (exploratory analysis). Supplementary Figure S1. ORCHARD study design. Supplementary Figure S2. (A) Kaplan–Meier analysis and (B) Swimmer plot for duration of response among patients with a confirmed response per RECIST 1.1. Supplementary Figure S3. (A) Scatter plot of best percentage change from baseline in target lesion size with table of objective response rate per RECIST 1.1 and (B) Kaplan–Meier analysis of progression-free survival by EGFR C797S clonality (exploratory analyses). 2026-10-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34040787 https://figshare.com/articles/journal_contribution/Supplementary_Data1_from_Osimertinib_plus_Gefitinib_in_Patients_with_i_EGFR_i_-Mutated_Advanced_Non_Small_Cell_Lung_Cancer_and_i_EGFR_i_C797X_Mutation_Following_First-Line_Osimertinib_ORCHARD/34040787 CC BY